Rational Design of HIV Vaccines and Microbicides
Author Information
Author(s): Sarah Brinckmann, Kelly da Costa, Marit J van Gils, David Hallengärd, Katja Klein, Luisa Madeira, Lara Mainetti, Paolo Palma, Katharina Raue, David Reinhart, Marc Reudelsterz, Nicolas Ruffin, Janna Seifried, Katrein Schäfer, Enas Sheik-Khalil, Annette Sköld, Hannes Uchtenhagen, Nicolas Vabret, Serena Ziglio, Robin Shattock, Britta Wahren, Frances Gotch
Hypothesis
How can the EUROPRISE network contribute to the development of effective HIV vaccines and microbicides?
Conclusion
The EUROPRISE network is making significant progress in developing novel strategies for HIV prevention through vaccines and microbicides.
Supporting Evidence
- EUROPRISE is involved in 31 separate world-wide trials of vaccines and microbicides.
- The CAPRISA trial showed that a Tenofovir gel provided around 50% protection against HIV infection.
- Participants discussed the need for novel prevention combinations to enhance effectiveness.
Takeaway
Scientists are working together to create better ways to prevent HIV, like vaccines and gels that women can use to protect themselves.
Methodology
The review summarizes discussions and findings from the EUROPRISE network's annual conference, focusing on ongoing research and trials.
Limitations
The high cost and length of clinical trials limit the number of studies that can be conducted.
Participant Demographics
Participants included over 50 institutions from 13 European countries and 3 industrial partners.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website